Salt Lake City, UT. — October 10, 2016. Knudra Transgenics, a genome engineering company specializing in building transgenic model organisms for research and drug discovery, has entered into a co-marketing partnership with Nemametrix Inc., a fast-growing life sciences startup that created the innovative ScreenChip System for drug screening, mutant phenotyping, and toxicological assessment.
Uniquely aligned in their mission to reinvent how diseases are researched, Nemametrix and Knudra Transgenics will work together to expand access to new markets and sales opportunities in academic and commercial labs around the world.
“We are thrilled to partner with Knudra, a company with proven technical expertise in C. elegans genome engineering as demonstrated by their groundbreaking RediModel System and RecombiREAD technologies,” said Matt Beaudet, CEO of Nemametrix. “Paired with our ScreenChip System platform, we expect this partnership will dramatically expand our reach into labs that have not traditionally used C. elegans — enabling new breakthroughs in ALS, Alzheimer’s disease, and anti-aging research with our combined capabilities.”
As part of the co-marketing partnership, Nemametrix and Knudra Transgenics will cooperate on marketing materials, research, and resources. This will include a co-presentation at the American Society for Cell Biology (ASCB) 2016 meeting entitled Whole animal data for cell biologists: extend your understanding of your genes, proteins, and pathways with accessible in vivo research. Both companies will also have shared exhibits at the ASCB meeting being held on December 3rd and the Society for Neuroscience meeting on November 12th 2016.
Potential for further marketing, sales, and co-development partnerships between Nemametrix and Knudra are in the works. “In working with Nemametrix, we expand the reach of our service platform. The research client gains access to a series of validated disease models in our easy-to-use RediModel System. Then, by analyzing the animal model on Nemametrix’s ScreenChip System, the researcher can quickly characterize the role of human disease gene polymorphisms for their contribution to disease pathogenesis. We expect the combined platform strengths wilt lead to a significant acceleration of the pace of medical research and discovery. This agreement is our first step on the path to a long and productive relationship with Nemametrix,” said Knudra’s founder Chris Hopkins. “This is an exciting period of growth the C. elegans community.”
About Nemametrix. NemaMetrix is a biotech company located in Eugene, Oregon driving discovery in animal models of human disease using C. elegans screening and phenomics. Maintaining active collaborations within the academic research community, we help provide insights into complex biological mechanisms through our core technology, which integrates microfluidics and electrophysiology.
About Knudra Transgenics. Knudra Transgenics is located in Salt Lake City, Utah and specializes in transgenesis services in C. elegans and zebrafish. From the affordably priced Inject Express service to the premium Full Build service, clients receive products that accelerate their research progress and scientific knowledge.